Skandinaviska Enskilda Banken (SEB)
BIO icon

Skandinaviska Enskilda Banken (SEB)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,731
Closed -$909K – 850
2025
Q1 		$909K Hold
3,731
– – ﹤0.01% 650
2024
Q4 		$1.22M Sell
3,731
-100
-3% -$33.9K 0.01% 637
2024
Q3 		$1.28M Hold
3,831
– – 0.01% 649
2024
Q2 		$1.05M Hold
3,831
– – 0.01% 639
2024
Q1 		$1.33M Hold
3,831
– – 0.01% 638
2023
Q4 		$1.24M Sell
3,831
-158
-4% -$49.5K 0.01% 662
2023
Q3 		$1.43M Sell
3,989
-17
-0.4% -$6.56K 0.01% 616
2023
Q2 		$1.52M Buy
4,006
+132
+3% +$53.7K 0.01% 618
2023
Q1 		$1.86M Sell
3,874
-94
-2% -$44K 0.01% 567
2022
Q4 		$1.67M Buy
3,968
+284
+8% +$115K 0.01% 576
2022
Q3 		$1.54M Sell
3,684
-1,122
-23% -$559K 0.01% 594
2022
Q2 		$2.38M Sell
4,806
-401
-8% -$209K 0.02% 527
2022
Q1 		$2.93M Sell
5,207
-485
-9% -$292K 0.02% 532
2021
Q4 		$4.32M Sell
5,692
-160
-3% -$120K 0.02% 452
2021
Q3 		$4.37M Buy
5,852
+68
+1% +$50.9K 0.02% 445
2021
Q2 		$3.73M Buy
5,784
+334
+6% +$203K 0.02% 483
2021
Q1 		$3.11M Buy
5,450
+57
+1% +$33.8K 0.02% 521
2020
Q4 		$3.14M Sell
5,393
-69
-1% -$39.3K 0.02% 498
2020
Q3 		$2.81M Buy
5,462
+3,841
+237% +$1.95M 0.02% 471
2020
Q2 		$732K Buy
1,621
+221
+16% +$97.5K 0.01% 766
2020
Q1 		$491K Buy
1,400
+100
+8% +$36.8K 0.01% 748
2019
Q4 		$481K Buy
+1,300
New +$458K ﹤0.01% 803

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s BIO Position: Q2 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 3,731 shares — an estimated $909K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in BIO in Q4 2019 and held it in 22 quarters. The position peaked at $4.37M in Q3 2021. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 3,731 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $909K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 22 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Bio-Rad Laboratories Class A position peaked at $4.37M in Q3 2021.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2025, filed 13 Aug 2025.